• +1-646-491-9876
    • +91-20-67278686

    Search

    Systemic Mastocytosis Pipeline Review H1 2017

    Systemic Mastocytosis Pipeline Review H1 2017

    • Report Code ID: RW0001799286
    • Category Pharmaceuticals
    • No. of Pages 132
    • Publication Month May-17
    • Publisher Name Global Markets Direct
    Systemic Mastocytosis - Pipeline Review, H1 2017

    Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Systemic Mastocytosis - Pipeline Review, H1 2017, provides an overview of the Systemic Mastocytosis (Gastrointestinal) pipeline landscape.

    Systemic mastocytosis is a disorder where mast cells are abnormally increased in multiple organs including the bone marrow. Symptoms include shortness of breath, low blood pressure, hives and swelling, itching, diarrhea, headache, flushing and musculoskeletal pain. Treatment includes antihistamines and more aggressive forms of Systemic mastocytosis require interferon or chemotherapeutic agents.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Systemic Mastocytosis - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Systemic Mastocytosis (Gastrointestinal) , complete with analysis by stage of development, drug target, mechanism of action (MoA) , route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Systemic Mastocytosis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Systemic Mastocytosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase II, Phase I and Preclinical stages are 2, 5, 3 and 1 respectively.

    Systemic Mastocytosis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Systemic Mastocytosis (Gastrointestinal) .
    - The pipeline guide reviews pipeline therapeutics for Systemic Mastocytosis (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Systemic Mastocytosis (Gastrointestinal) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Systemic Mastocytosis (Gastrointestinal) therapeutics based on mechanism of action (MoA) , drug target, route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Systemic Mastocytosis (Gastrointestinal)

    Reasons to buy

    - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Systemic Mastocytosis (Gastrointestinal) .
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Systemic Mastocytosis (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents
    List of Tables
    List of Figures
    Introduction
    Publisher Report Coverage
    Systemic Mastocytosis - Overview
    Systemic Mastocytosis - Therapeutics Development
    Pipeline Overview
    Pipeline by Companies
    Products under Development by Companies
    Systemic Mastocytosis - Therapeutics Assessment
    Assessment by Target
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Systemic Mastocytosis - Companies Involved in Therapeutics Development
    AB Science SA
    AbbVie Inc
    Arog Pharmaceuticals Inc
    Blueprint Medicines Corp
    Bristol-Myers Squibb Company
    Deciphera Pharmaceuticals LLC
    Novartis AG
    Patara Pharma Inc
    Seattle Genetics Inc
    Stemline Therapeutics Inc
    Systemic Mastocytosis - Drug Profiles
    AK-002 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    BLU-285 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    brentuximab vedotin - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    crenolanib besylate - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    cromolyn sodium - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    dasatinib - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    DCC-2618 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    ibrutinib - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    masitinib - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    midostaurin - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    SL-401 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Systemic Mastocytosis - Discontinued Products
    Systemic Mastocytosis - Product Development Milestones
    Featured News & Press Releases
    Mar 27, 2017: Blueprint Medicines to Present on BLU-285 at Upcoming Scientific Conferences
    Jan 09, 2017: AB Science announces publication in The Lancet of phase 3 clinical trial results demonstrating masitinib is effective and well tolerated in the treatment of adult patients with severe indolent systemic mastocytosis
    Dec 04, 2016: Blueprint Medicines Announces Proof-of-Concept Data from Phase 1 Clinical Trial of BLU-285 in Patients with Advanced Systemic Mastocytosis
    Dec 01, 2016: AB Science will present phase 3 results in severe s ystemic mastocytosis at the Journées Dermatologiques de Paris 2016
    Nov 14, 2016: Novartis drug PKC412 (midostaurin) C for newly-diagnosed FLT3-mutated AML and advanced systemic mastocytosis
    Nov 03, 2016: Blueprint Medicines to Present Preliminary Data from Ongoing Phase 1 Clinical Trial for BLU-285 in Advanced Systemic Mastocytosis at 2016 ASH Annual Meeting
    Oct 31, 2016: Deciphera Pharmaceuticals to Present Clinical Data on DCC-2618 at 28th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
    Oct 28, 2016: Blueprint Medicines to Present Preclinical Data and Provide Enrollment Updates for Phase 1 Clinical Trial for BLU-285 in Advanced Systemic Mastocytosis at ECNM Annual Meeting 2016
    Sep 15, 2016: Allakos Begins Clinical Trials of AK002 in Patients with Systemic Mastocytosis
    Jun 29, 2016: Novartis PKC412 (midostaurin) pivotal data published in NEJM show 60% response rate in advanced systemic mastocytosis (SM)
    May 30, 2016: AB Science will Present Phase 3 Data in Severe Systemic Mastocytosis at the International 21St Congress of the European Hematology Association
    May 02, 2016: AB Science has submitted to EMA the marketing authorization application for Masitinib in the Treatment of Severe Systemic Mastocytosis
    Feb 01, 2016: AB Science announces that Rapporteurs appointed by the EMA have recommended to file a marketing authorization application for full approval for masitinib in severe systemic mastocytosis
    Dec 07, 2015: AB Science announces results from Phase 3 randomized placebo-controlled trial of masitinib in adults with severe systemic mastocytosis unresponsive to optimal symptomatic treatment
    Nov 30, 2015: AB Science Announces Positive Top-Line Results from Phase 3 Trial of Masitinib in Adults with Severe Systemic Mastocytosis
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer

    List of Tables

    Number of Products under Development for Systemic Mastocytosis, H1 2017
    Number of Products under Development by Companies, H1 2017
    Products under Development by Companies, H1 2017
    Number of Products by Stage and Target, H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Systemic Mastocytosis - Pipeline by AB Science SA, H1 2017
    Systemic Mastocytosis - Pipeline by AbbVie Inc, H1 2017
    Systemic Mastocytosis - Pipeline by Arog Pharmaceuticals Inc, H1 2017
    Systemic Mastocytosis - Pipeline by Blueprint Medicines Corp, H1 2017
    Systemic Mastocytosis - Pipeline by Bristol-Myers Squibb Company, H1 2017
    Systemic Mastocytosis - Pipeline by Deciphera Pharmaceuticals LLC, H1 2017
    Systemic Mastocytosis - Pipeline by Novartis AG, H1 2017
    Systemic Mastocytosis - Pipeline by Patara Pharma Inc, H1 2017
    Systemic Mastocytosis - Pipeline by Seattle Genetics Inc, H1 2017
    Systemic Mastocytosis - Pipeline by Stemline Therapeutics Inc, H1 2017
    Systemic Mastocytosis - Discontinued Products, H1 2017

    List of Figures

    Number of Products under Development for Systemic Mastocytosis, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products by Top 10 Targets, H1 2017
    Number of Products by Stage and Top 10 Targets, H1 2017
    Number of Products by Top 10 Mechanism of Actions, H1 2017
    Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
    Number of Products by Routes of Administration, H1 2017
    Number of Products by Stage and Routes of Administration, H1 2017
    Number of Products by Molecule Types, H1 2017
    Number of Products by Stage and Molecule Types, H1 2017
    AB Science SA
    AbbVie Inc
    Arog Pharmaceuticals Inc
    Blueprint Medicines Corp
    Bristol-Myers Squibb Company
    Deciphera Pharmaceuticals LLC
    Novartis AG
    Patara Pharma Inc
    Seattle Genetics Inc
    Stemline Therapeutics Inc

    Request for Sample

    Report Url http://www.reportsweb.com//systemic-mastocytosis-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//systemic-mastocytosis-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//systemic-mastocytosis-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments